You are here: Industry Insights > drug

News List

New drugs more likely to be approved if backed up by genetics, says study europeanpharmaceuticalreview
December 16, 2019
A recent study has reported that a new drug candidate is more likely to be approved for use if it targets a gene known to be linked to the disease.
Multiple sclerosis drug market predicted to reach $32.9bn by 2028 europeanpharmaceuticalreview
December 12, 2019
Driven by the launch of various pipeline agents, a new report has projected that the multiple sclerosis therapeutics market will reach $32.9 billion in 2028.
Jubilant Biosys Expands Discovery Capabilities ContractPharma
December 11, 2019
Begins major capacity expansions for its drug discovery services business.
Almac Awarded $200,000 BMGF Grant ContractPharma
December 11, 2019
Will work to develop novel biocatalytic routes to Etonorgestrel and Levonorgestrel APIs.
UCB Trial Achieves Endpoints ContractPharma
December 11, 2019
Phase III study met its co-primary and secondary endpoints demonstrating superiority of bimekizumab to Abbvie’s Humira in plaque psoriasis
Erenumab migraine drug fails to meet NICE recommendation standards europeanpharmaceuticalreview
September 27, 2019
NICE has announced that it will not be recommending erenumab, an injectable migraine treatment, due to issues with cost and its long-term effectiveness.
Global injectable drug delivery market predicted to grow 12.8 percent europeanpharmaceuticalreview
September 26, 2019
Increasing demand for convenient drug delivery, as well as an increase in diseases such as diabetes, has fuelled the global injectable drug delivery market.
Losartan drug recall expanded to include five more lots europeanpharmaceuticalreview
September 26, 2019
FDA announces the voluntary recall for the losartan medications has been extended to include more lots, after impurities were found in the drugs.
Omega Therapeutics launches with focus on epigenetic drugs pharmaceutical-technology
September 25, 2019
US-based Flagship Pioneering has launched a genomics medicine company, Omega Therapeutics, to develop drugs that will leverage the human genome to cure or treat various diseases.
EC Grants Orphan Drug Designation for Nirogacestat for Soft Tissue Sarcoma americanpharmaceuticalreview
September 25, 2019
SpringWorks Therapeutics announced the European Commission has granted Orphan Drug Designation for nirogacestat, an oral, selective, small molecule, gamma-secretase inhibitor, for the treatment of soft tissue sarcoma.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 49 50 Next page